PRECISIS, a medical technology company developing targeted neuromodulation therapies, has been selected to receive the EIB Innovation Champion Award at the TechEU Equity Summit in Luxembourg.
The award recognises PRECISIS as one of Europe’s innovative companies developing new technologies and solutions with the potential to make a meaningful difference to people’s lives.
PRECISIS’ lead product, EASEE, is a targeted, reversible neurostimulation therapy for people with drug-resistant focal epilepsy and is available on the NHS. The minimally invasive system delivers electrical stimulation through an electrode placed beneath the scalp and above the skull, without contacting the brain, providing a new treatment approach for eligible patients.
“We are very proud to receive this recognition from the European Investment Bank. It reflects the ambition of our team to develop new treatment options for people living with drug-resistant epilepsy and to bring that innovation beyond the technology itself into clinical practice,” says Karl Stoklosa, CEO of PRECISIS. “The recognition also comes at an important time for PRECISIS as we continue to grow our presence in Europe and prepare for the next phase of our international development.”
This awards builds on the EIB’s partnership with PRECISIS. In 2025, the European Investment Bank provided the company with a €20 million venture loan to support the clinical and commercial development of EASEE and its international expansion.
“EASEE is the result of years of scientific and technological innovation, and this award is a great recognition of the team that has brought that innovation into clinical practice,” says Michael Tittelbach, CTO of PRECISIS. “Building on the support we have received, we are now looking towards the next generation of neurotechnology, exploring new closed-loop device concepts that leverage the potential of advanced AI algorithms and edge computing. We are excited to continue develop technology for neurological care.”
